Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3539638

CC1CCN(c2cc(N3CCNCC3)ccc2N)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.50
LGMN Q99538 4/20 0.49
GAA P10253 4/20 0.46
KDM4E B2RXH2 3/20 0.46
POLB P06746 1/20 0.46
NR4A1 P22736 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MAPT P10636 4/20 0.44
HTT P42858 3/20 0.44
MAPK1 P28482 2/20 0.44
RECQL P46063 2/20 0.44
PTK2B Q14289 1/20 0.44
USP2 O75604 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
S100B P04271 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3958578 0.88 GAA (0.55) CSF1RLGMNGAAKDM4EPOLB
Trifluoroacetic Acid SCHEMBL3539634 0.87 CSF1R (0.46) CSF1RGAAKDM4EPOLBNR4A1
Trifluoroacetic Acid SCHEMBL3543650 0.83 CSF1R (0.53) CSF1RLGMNGAAKDM4EPOLB
SCHEMBL3539636 0.81 CSF1R (0.61) CSF1RGAAUSP2MEN1KMT2A
Trifluoroacetic Acid SCHEMBL3539482 0.81 MAPT (0.64) CSF1RLGMNGAAKDM4EHSD17B10
SCHEMBL27691384 0.79 LGMN (0.55) CSF1RLGMNGAAKDM4EPOLB
SCHEMBL3958572 0.78 CSF1R (0.52) CSF1RLGMNGAAKDM4EPOLB
Trifluoroacetic Acid SCHEMBL3070914 0.77 GAA (0.72) GAAKDM4EPOLBNR4A1HSD17B10
SCHEMBL3539723 0.76 LGMN (0.55) CSF1RLGMNGAAKDM4EPOLB
Trifluoroacetic Acid SCHEMBL3545926 0.74 MAPT (0.66) CSF1RLGMNGAAKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES CSF1R 34/4885LGMN 3741/4885GAA 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.